Pharmaceutical

Novartis eyes first-line status for its radionucleotide therapy Lutathera

The Phase III trial of Luthathera as a first-line therapy showed improved progression-free survival in treating GEP-NETs.

Sep 25, 2023 - 20:00
Novartis eyes first-line status for its radionucleotide therapy Lutathera
The Phase III trial of Luthathera as a first-line therapy showed improved progression-free survival in treating GEP-NETs.
Read the original article

Tags:

Previous Article

Signal: AbbVie ends multi-million dollar cancer drug deal with I-Mab

Next Article

China’s NMPA approves Henlius’ oesophageal cancer therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease

Johnson & Johnson seeks FDA approval for Tremfya for Cr...

Jun 22, 2024

UnitedHealth’s rehab restrictions, Texas medical school drama, and health care’s biggest profits

UnitedHealth’s rehab restrictions, Texas medical school...

Jan 2, 2024

A Parkinson’s ‘game changer,’ backed by Michael J. Fox, could lead to new diagnostics and, someday, treatments

A Parkinson’s ‘game changer,’ backed by Michael J. Fox,...

Apr 13, 2023